The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156
Timeframe: 1 Cycle (21 days)
Phase 1a: To determine the RP2D or optimal dose of LY4170156 with bevacizumab
Timeframe: 1 Cycle (21 days)
Phase 1a: To determine the RP2D or optimal dose of LY4170156 with carboplatin
Timeframe: 1 Cycle (21 days)
Phase 1a: To determine the RP2D or optimal dose of LY4170156 with pembrolizumab
Timeframe: 1 Cycle (21 days)
Phase 1b: To assess the antitumor activity of LY4170156 Monotherapy: Overall response rate (ORR)
Timeframe: Up to Approximately 48 Months or 4 Years
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Timeframe: Up to Approximately 48 Months or 4 Years
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or